Top

BMC Nephrology

Published in:

Open Access 01-12-2012 | Research article

Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

Authors: Alicja E Grzegorzewska, Piotr M Wobszal, Adrianna Mostowska, Paweł P Jagodziński

Published in: BMC Nephrology | Issue 1/2012

Abstract

Background

The interleukin (IL)18 rs360719 CC genotype is associated with the development of antibodies to hepatitis B virus surface antigen (anti-HBs) in hemodialysis (HD) patients. IL18 shares biological properties with IL12 in promoting the T-hepler 1 (Th1) system. We studied whether polymorphisms in the IL12A 3` untranslated region (UTR) and IL12B 3`UTR may contribute to anti-HBs development (titre ≥ 10 IU/L) in HD patients either individually or jointly with the IL18 polymorphism.

Methods

In 518 HD patients and 240 controls the IL12A rs568408 3’UTR G > A polymorphism was genotyped by high-resolution melting curve analysis. Polymerase chain reaction restriction fragment length polymorphism was used to detect the IL12B rs3212227 3’UTR A > C and IL18 -1297 T > C rs360719 polymorphisms. The associations between the IL12A, IL12B and IL18 genotypes and the risk of impaired anti-HBs development were estimated by computing the odds ratios and their 95% confidence intervals using logistic regression analysis.

Results

In the logistic regression analysis, the higher frequency of rs360719 CC individually (2.9% in 207 patients without anti-HBs development vs 8.0% in 311 patients with anti-HBs development, p = 0.009) and of rs360719 CC combined with rs568408 GG (p = 0.048), rs568408 GA (p = 0.035), rs568408 GG/AA (p = 0.034) or rs3212227 AA (p = 0.046) was associated with an increased chance for the development of anti-HBs in HD patients. Patients bearing both rs568408 AA and rs360719 TT had a 10.9-fold or 8.9-fold lower chance, respectively, to develop anti-HBs compared with those carrying any other genotype (p = 0.005) or those who had both wild-type rs568408 GG and rs360719 TT (p = 0.011). Carriers of both rs3212227 CC and rs360719 TC had a 4.6-fold lower chance for anti-HBs development than carriers of any other genotype (p = 0.042).

Conclusion

Development of anti-HBs in HD patients is associated with gene polymorphisms of interleukins involved in the Th1 system.

Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann AU, Brosgart CL, Naoumov NV: Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother. 2008, 52: 312-320. 10.1128/AAC.00467-07.CrossRefPubMed

Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, Chang MH: Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010, 138: 165-172. 10.1053/j.gastro.2009.09.018.CrossRefPubMed

Rossol S, Marinos G, Carucci P, Singer MV, Roger W, Naoumov NV: Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest. 1997, 99: 3025-3033. 10.1172/JCI119498.CrossRefPubMedPubMedCentral

Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ, Lee JA, Park BL, Cheong HS, Shin HD, Cho BY, Kim JH: Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance. Dig Dis Sci. 2010, 55: 1113-1119. 10.1007/s10620-009-0819-z.CrossRefPubMed

Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH: Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol. 1998, 160: 1320-1329.PubMed

Schirmbeck R, Reimann J: Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology. 2001, 44: 115-123. 10.1159/000050038.CrossRefPubMed

Chen JZ, Zhu HH, Liu KZ, Chen Z: Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant. J Zhejiang Univ Sci. 2004, 5: 467-471. 10.1631/jzus.2004.0467.CrossRefPubMed

Channarong S, Mitrevej A, Sinchaipanid N, Usuwantim K, Kulkeaw K, Chaicumpa W: Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine. Asian Pac J Allergy Immunol. 2007, 25: 233-242.PubMed

Tang LL, Liu KZ: Recent advances in DNA vaccine of hepatitis virus. Hepatobiliary Pancreat Dis Int. 2002, 1: 228-231.PubMed

10.

Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995, 378: 88-91. 10.1038/378088a0.CrossRefPubMed

11.

Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998, 161: 3400-3407.PubMed

12.

Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, Okamura H, Nakanishi K: IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol. 2000, 12: 151-160. 10.1093/intimm/12.2.151.CrossRefPubMed

13.

Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, Dentchev T, Manson KH, Wyand MS, Agadjanyan MG, Ugen KE, Weiner DB: Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol. 1999, 28: 214-223. 10.1111/j.1600-0684.1999.tb00272.x.CrossRefPubMed

14.

Yang W, Chaudhri G, Jackson RJ, Karupiah G: IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a Poxvirus infection. J Immunol. 2009, 183: 3324-3331. 10.4049/jimmunol.0803985.CrossRef

15.

Reading PC, Whitney PG, Barr DP, Wojtasiak M, Mintern JD, Waithman J, Brooks AG: IL-18, but not IL-12, regulates NK cell activity following intranasal herpes simplex virus type 1 infection. J Immunol. 2007, 179: 3214-3221.CrossRefPubMed

16.

Harandi AM, Svennerholm B, Holmgren J, Eriksson K: Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J Virol. 2001, 75: 6705-6709. 10.1128/JVI.75.14.6705-6709.2001.CrossRefPubMedPubMedCentral

17.

Sánchez E, Palomino-Morales RJ, Ortego-Centeno N, Jiménez-Alonso J, González-Gay MA, López-Nevot MA, Sánchez-Román J, de Ramón E, González-Escribano MF, Pons-Estel BA, D'Alfonso S: Sebastiani GD; Italian collaborative group, Alarcón-Riquelme ME, Martín J: Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. Hum Mol Genet. 2009, 18: 3739-3748. 10.1093/hmg/ddp301.CrossRefPubMed

18.

Grzegorzewska AE, Wobszal P, Jagodziński PP: Interleukin-18 Promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res. 2012, 35: 1-8. 10.1159/000329932.CrossRefPubMed

19.

Recommendations for preventing transmission of infections among chronic hemodialysis patients: Morbidity and Mortality Weekly report. 2001, Centers for Disease Control and Prevention: Centers for Disease Control and Prevention, 50-

20.

Guidelines EBP: Prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant. 2002, 17: 78-87.

21.

Załączniki do rozporządzenia Ministra Zdrowia z dnia 18 kwietnia: 2005

22.

Hahn LW, Ritchie MD, Moore JH: Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003, 19: 376-382. 10.1093/bioinformatics/btf869.CrossRefPubMed

23.

Bruguera M, Cremades M, Mayor A, Sánchez Tapias JM, Rodés J: Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J. 1987, 63S (2): 155-158.

24.

Mitwalli A: Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron. 1996, 73: 417-420.PubMed

25.

Sorkhi H, Roushan MR: Al Hashemi GH, Dooki MR, Bai S: Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. East Mediterr Health J. 2008, 14: 798-803.PubMed

26.

Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P: Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther. 2005, 21: 1341-1347. 10.1111/j.1365-2036.2005.02501.x.CrossRefPubMed

27.

Sun HY, Lee HC, Liu CE, Yang CL, Su SC, Ko WC, Lin CY, Tsai JJ, Wong WW, Ho MW, Cheng SH, Lin YH, Miao WJ, Hung CC: Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat. 2010, 17: 578-587.CrossRefPubMed

28.

Grzegorzewska AE, Kaczmarek-Leki V, Młot-Michalska M, Niepolski L: Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant. 2011, 26: 970-976. 10.1093/ndt/gfq499.CrossRefPubMed

29.

Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, Müller C: HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int. 1995, 48: 1967-1971. 10.1038/ki.1995.498.CrossRefPubMed

30.

Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C: Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004, 40: 1072-1077. 10.1002/hep.20435.CrossRefPubMed

31.

Grzegorzewska AE, Kurzawska-Firlej D, Ratajewski W, Frankiewicz D, Niepolski L, Kaczmarek A: Antibodies to core antigen of hepatitis B virus in patients on renal replacement therapy: Association with demographic, clinical and laboratory data. Nephron Clin Pract. 2010, 114: c194-c203. 10.1159/000262302.CrossRefPubMed

32.

Fabrizi F, Dixit V, Martin P, Messa P: Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther. 2011, 33: 815-821. 10.1111/j.1365-2036.2011.04589.x.CrossRefPubMed

33.

Shatat HZ, Kotkat AM, Farghaly AG: Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc. 2000, 75: 257-275.PubMed

34.

Steketee RW, Ziarnik ME, Davis JP: Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. Am J Epidemiol. 1988, 127: 772-782.PubMed

35.

Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, Erba G, Locatelli F: Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron. 1996, 72: 536-543.PubMed

36.

He Q, Wu F, Zhang P, Chen J: Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients. Postgrad Med. 2011, 123: 150-152.CrossRefPubMed

37.

Watanabe H, Matsushita S, Kamikawaji N, Hirayama K, Okumura M, Sasazuki T: Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Immunol. 1988, 22: 9-17. 10.1016/0198-8859(88)90047-X.CrossRefPubMed

38.

Hatae K, Kimura A, Okubo R, Watanabe H, Erlich HA, Ueda K, Nishimura Y, Sasazuki T: Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol. 1992, 22: 1899-1905. 10.1002/eji.1830220733.CrossRefPubMed

39.

Girndt M, Sester U, Sester M, Deman E, Ulrich C, Kaul H, Köhler H: The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001, 60: 2385-2391. 10.1046/j.1523-1755.2001.00062.x.CrossRefPubMed

40.

Seder RA, Gazzinelli R, Sher A, Paul WE: IL-12 acts directly on CD41 T cells to enhance priming for IFN-g production and diminishes IL-4 inhibition in such priming. Proc Natl Acad Sci USA. 1993, 90: 10188-10192. 10.1073/pnas.90.21.10188.CrossRefPubMedPubMedCentral

41.

Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P, Trinchieri G: Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol. 1995, 25: 672-676. 10.1002/eji.1830250307.CrossRefPubMed

42.

Cheema BS, Abas H, Smith BC, O'Sullivan AJ, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, Berger K, Baune BT: Fiatarone Singh MA: Effect of resistance training during hemodialysis on circulating cytokines: a randomized controlled trial. Eur J Appl Physiol. 2011, 111: 1437-1445. 10.1007/s00421-010-1763-5.CrossRefPubMed

43.

Ishizuka T, Nitta K, Yokoyama T, Hayashi T, Futatsuyama K, Kimata N, Miwa N, Nishida E, Kawashima A, Akiba T, Nihei H: Increased serum levels of interleukin-12 may be associated with Th1 differentiation in hemodialysis patients. Nephron. 2002, 90: 503-504. 10.1159/000054742.CrossRefPubMed

44.

Klínger J, Enríquez J, Arturo JA, Delgado M, Avila G, Ceballos O: Cytokines and peritonitis in continuous ambulatory peritoneal dialysis: immunodeviation and immunodeficiency. Adv Perit Dial. 2002, 18: 170-176.PubMed

45.

Libetta C, Rampino T: Dal Canton A: Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis. 2001, 38: 286-295. 10.1053/ajkd.2001.26092.CrossRefPubMed

46.

Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M: T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant. 2000, 15: 1217-1223. 10.1093/ndt/15.8.1217.CrossRefPubMed

47.

Lonnemann G, Novick D, Rubinstein M, Dinarello CA: Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol. 2003, 60: 327-334.CrossRefPubMed

48.

Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, Liu J, Liu S, Ji G, Shi H, Shen H, Hu Z: IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011, 128: 1692-1696. 10.1002/ijc.25488.CrossRefPubMed

49.

Morahan G, Huang D, Ymer SI, Cancilla MR, Stephen K, Dabadghao P, Werther G, Tait BD, Harrison LC, Colman PG: Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet. 2001, 27: 218-221. 10.1038/84872.CrossRefPubMed

50.

Davoodi-Semiromi A, Yang JJ, She JX: IL-12p40 is associated with type 1 diabetes in Caucasian-American families. Diabetes. 2002, 51: 2334-2336. 10.2337/diabetes.51.7.2334.CrossRefPubMed

51.

Seegers D, Zwiers A, Strober W, Peña AS, Bouma G: Taq I polymorphism in the 3_-UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun. 2002, 3: 419-423. 10.1038/sj.gene.6363919.CrossRefPubMed

52.

Yilmaz V, Yentür SP, Saruhan-Direskeneli G: IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine. 2005, 30: 188-194. 10.1016/j.cyto.2005.01.006.CrossRefPubMed

53.

Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, Moore C, Pollard AJ, Rayco-Solon P, Sirugo G, van der Sande MA, Waight P, Whittle HC, Zaman SM, Hill AV, Hall AJ: Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One. 2008, 3: e1898-10.1371/journal.pone.0001898.CrossRefPubMedPubMedCentral

54.

Du DW, Jia ZS, Li GY, Zhou YY: HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection. World J Gastroenterol. 2003, 9: 108-111.CrossRefPubMedPubMedCentral

55.

Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A: Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol. 1999, 162: 3088-3095.PubMed

56.

Izakovicova Holla L, Hrdlicková B, Schüller M, Buckova D, Kindlova D, Izakovic V, Vasku A: Haplotype analysis of the interleukin-18 gene in Czech patients with allergic disorders. Hum Immunol. 2010, 71: 592-597. 10.1016/j.humimm.2010.03.004.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/13/75/prepub

Title: Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients
Authors: Alicja E Grzegorzewska
Piotr M Wobszal
Adrianna Mostowska
Paweł P Jagodziński
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2012
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/1471-2369-13-75

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Geriatric urolithiasis in the emergency department: risk factors for hospitalisation and emergency management patterns of acute urolithiasis

Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study

Picking transplant glomerulopathy out of the CAN: evidence from a clinico-pathological evaluation

Reduced incidence of end stage renal disease among the elderly in Denmark: an observational study

Pro-/anti-inflammatory cytokine gene polymorphisms and chronic kidney disease: a cross-sectional study

Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials